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Purpose: Inhospital death is commonly used as an outcome measure. However, it may 
be a biased measure of overall fatal outcome. The objective of this study was to evaluate 
inhospital death as a measure of all-cause 30-day case fatality in patients with bloodstream 
infection (BSI).
Patients and methods: A population-based surveillance cohort study was conducted, and 
patients who died in hospital within 30 days (30-day inhospital death) were compared with 
those who died in any location by day 30 post BSI diagnosis (30-day all-cause case fatality).
Results: A total of 1,773 residents had first incident episodes of BSI. Overall, 299 patients 
died for a 30-day all-cause case fatality rate of 16.9%. Most (1,587; 89.5%) of the patients were 
admitted to hospital, and ten (5.4%) of the 186 patients not admitted to hospital died. Of the 1,587 
admitted patients, 242 died for a 30-day inhospital death rate of 15.2%. A further 47 patients 
admitted to hospital died after discharge but within 30 days of BSI diagnosis for a 30-day case 
fatality rate among admitted patients of 18.2%. Patients who died following discharge within 
30 days were older and more likely to have dementia.
Conclusion: The use of inhospital death is a biased measure of true case fatality.
Keywords: mortality, case fatality, bacteremia
Introduction
Vital status, either survival or death, is the most commonly utilized outcome measure 
in clinical studies.1–4 Use of all-cause case fatality at a defined time period of obser-
vation as an outcome measure has a number of benefits not limited to the fact that it 
is binary, clinically relevant, and is free from subjective observer interpretation bias. 
However, in many studies, vital status information is available only for hospitalized 
patients during their inpatient stay. As a result, inhospital death is commonly used as 
a surrogate measure of all-cause case fatality.5–7 Management of patients without hos-
pitalization or differential lengths of hospital stay or patient deaths following transfer 
to another facility or the community during the period of follow-up among admitted 
patients may therefore introduce bias in the ascertainment of fatal outcome. This is of 
relevance given that there have been important shifts in the delivery of health care in 
recent years with emphasis on shorter duration of hospital stay and increased delivery 
of advanced care in the community setting.
Despite its widespread use, the validity of inhospital death as a surrogate measure 
of defined-day all-cause case fatality has not been well established. The objective of 
this study was to assess the use of inhospital death as compared to all-cause 30-day case 
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fatality rates among a population-based cohort of patients 
with bloodstream infections (BSIs).
Patients and methods
study population
Surveillance was conducted in the western interior region 
of British Columbia, Canada (2016 population, 182,422). 
This geographically diverse and large area encompasses the 
city of Kamloops (2016 population 114,429) and a number 
of other smaller communities.8 Within the region, there are 
six hospitals with tertiary care provided at the Royal Inland 
Hospital in Kamloops. Most patients are cared for exclusively 
within the regional facilities although patients who require 
management for major burns, acute organ transplantation, 
cardiac or thoracic surgery, invasive cardiology procedures, 
and some other highly specialized services are transferred 
to other facilities outside the region for at least part of their 
care. Surveillance included all western interior residents with 
incident BSI occurred between April 1, 2010, and March 
31, 2017. This study was approved by the Interior Health 
Research Ethics Board (201314052-I).
Population-based surveillance
Active surveillance was conducted using a population-based 
design.9 The regional microbiology laboratory identified all 
incident episodes of BSI occurring among western interior 
residents including those occurring in both hospitals and 
the community. An experienced infectious disease consul-
tant reviewed the electronic medical record of all cases and 
recorded clinical and outcome variables and assigned a most 
likely focus of infection. Comorbid illnesses were classified 
using the Charlson score.10 Vital status was ascertained using 
the electronic health record that is populated through a direct 
linkage between the regional enterprise master patient index 
and provincial vital statistics database that registers all deaths 
occurring anywhere within the province.
Laboratory and study definitions
The BacT/Alert 3D System (bioMerieux, Craponne, France) 
was used to culture blood during the study. Blood cultures 
were considered as a set consisting of growth of an organism 
within an anaerobic/aerobic pair from a single draw. In our 
region, usual practice is to draw two independent sets from 
different sites per order. We defined a BSI incident by the first 
isolate per patient per clinical infection episode and repeat 
isolation of the same organism within 30 days were deemed to 
represent the same episode. Patients who had more than one 
incident isolates of different species within a 48-hour period 
were classified as having polymicrobial BSI. We excluded 
contaminants based on a clinical review of all available labo-
ratory, diagnostic, and clinical information. Hospital-onset 
BSIs were those where the first blood culture was drawn ≥48 
hours after hospital admission.11 Community-onset infections 
were those which occurred among patients not admitted or 
within the first 48 hours of admission to hospital and were 
subcategorized as either community associated or health-
care associated by applying the criteria of Friedman et al.12 
Transfers of patients between hospitals were considered to 
represent a single continuous admission.
Inhospital death was defined as deaths within 30 days 
of index BSI among patients admitted to hospital and was 
censored at discharge; patients who were alive in hospital 
or discharged alive prior to day 30 were deemed to not have 
inhospital death. Patients who died in any location within 30 
days of BSI diagnosis were deemed to have all-cause 30-day 
case fatality.
statistical analyses
Data were managed and analyzed using Stata (version 15.1; 
StataCorp LP, College Station, TX, USA). Prior to analysis, 
the individual patient’s data were anonymized. The primary 
analysis was the comparison of inhospital and all-cause 
30-day case fatality rates. An a priori specified secondary 
analysis included comparison between all-cause case fatality 
and inhospital death rates at 7, 14, 21, 30, and 90 days. Cat-
egorical data were compared using Fisher’s exact test. Skewed 
continuously distributed variables were reported as median 
with IQR and were compared with the Mann–Whitney test.
Results
During the 7 years of surveillance, 1,773 area residents had 
first incident episodes of BSI. The median age was 67.8 
(IQR, 54.4–78.4) years, and 944 (53.4%) were male. Cases 
included 266 (15.0%) that were hospital onset, 833 (47.0%) 
were health care associated, and 674 (38.0%) were commu-
nity associated. Most (1,587; 89.5%) of the patients were 
admitted to hospital for management as shown in Figure 1. 
The median length of stay for admitted patients was 9 (IQR, 
5–20) days, and this did not vary significantly by the study 
year (P=0.06).
Overall, 299/1,773 patients died within 30 days of BSI at 
an all-cause 30-day case fatality rate of 16.9%. Ten (5.4%) of 
the 186 patients not admitted to hospital died, and therefore 
the death rate among those admitted to hospital was 15.2% 
(242/1,587). Forty-seven patients admitted to hospital died 
after discharge but within 30 days of BSI diagnosis for a 
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hospital mortality is a biased measure of case fatality
30-day case fatality rate among admitted patients (n=1,587) 
of 18.2%. The proportion of patients who died within 30 
days of hospitalization either in hospital or after discharge 
did not vary significantly (P=0.7) during the study period.
Among the cohort of admitted patients who died within 
30 days of index BSI (n=289), those who died following 
discharge were significantly older and more likely to have 
dementia than those who died during hospitalization within 
30 days as summarized in Table 1.
Figure 1 incidence and outcomes of Bsi at 30 days of follow-up, western interior of British Columbia, 2010–2017.
Abbreviation: Bsi, bloodstream infection.
Incident BSI
cases
(n=1,773)
Admitted
(n=1,587)
Not admitted
(n=186)
Survivors
(n=176)Deaths (n=10)
Survivors
(n=1,298)
Death after
discharge (n=47)
Inhospital
deaths (n=242)
Table 1 Comparison of admitted patients who died during hospitalization or after discharge within 30 days of Bsi
Variable Death during hospital  
stay (n=242)
Death after hospital  
discharge (n=47)
RR (95% CI) death  
after discharge
P-value
Median age (iQr) (years) 72.9 (63.2–81.3) 78.5 (64.9–84.0) – 0.035
Male 128 (53%) 31 (66%) 1.2 (1.0–1.6) 0.1
acquisition
hospital onset
health care associated
Community associated
79 (33%)
117 (48%)
46 (19%)
11 (23%)
29 (62%)
7 (15%)
– 0.6
Median Charlson score (iQr) 2 (1–4) 3 (1–6) – 0.2
Myocardial infarction 20 (8%) 5 (11%) 1.3 (0.5–3.3) 0.6
Congestive heart failure 29 (12%) 9 (19%) 1.6 (0.8–3.2) 0.2
Peripheral vascular disease 14 (6%) 3 (6%) 1.1 (0.3–3.7) 0.9
Cerebrovascular accident 28 (12%) 3 (6%) 0.6 (0.2–1.7) 0.3
hemiplegia 3 (1%) 0 – 0.4
Chronic lung disease 49 (20%) 10 (21%) 1.1 (0.6–1.9) 0.9
Diabetes mellitus 44 (18%) 12 (26%) 1.4 (0.8–2.5) 0.2
renal disease 27 (11%) 7 (15%) 1.1 (0.5–2.4) 0.5
liver disease 36 (15%) 5 (11%) 0.7 (0.3–1.7) 0.4
Peptic ulcer disease 15 (6%) 2 (4%) 0.7 (.2–2.9) 0.6
Cancer 90 (37%) 21 (45%) 1.2 (0.8–1.7) 0.3
Dementia 20 (8%) 13 (28%) 3.3 (1.8–6.2) <0.001
rheumatic disease 14 (6%) 4 (9%) 1.5 (0.5–4.3) 0.5
hiV/aiDs 2 (1%) 0   
Abbreviation: Bsi, bloodstream infection.
Among the 47 patients who died after hospital discharge 
but within 30 days of the index BSI, most deaths were not 
unexpected. These included a documented palliative approach 
in 35 (74.5%) cases of which 15 of these were discharged to 
hospice. Among the other 12 (25.5%) patients, six were dis-
charged to nursing homes, three patients were transferred out 
of the region for quaternary care, one patient was likely under 
palliative care (based on comorbidities but not explicitly docu-
mented as such), and details were lacking on the remaining two.
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The degree to which inhospital death underestimated 
30-day case fatality increased with longer durations of follow-
up as shown in Figure 2. There was a progressive increase in 
the proportion of post-discharge deaths with longer follow-
up duration that was most notable at day 90, where 31% 
(120/384) deaths were post-hospital discharge (Figure 2).
Discussion
We demonstrate that, in our population, determination of 
the proportion of patients with BSI who die is dependent 
on how death is ascertained. All-cause 30-day case fatality 
rate was established as the “gold standard” outcome for our 
study.13 This choice was based on the fact that this outcome 
was independent of decisions to admit or discharge patients 
and 1 month (28 or 30 days) of follow-up has traditionally 
been the standard duration of follow-up in clinical trials and 
observational studies of sepsis and BSI.7 We observed that the 
“true” all-cause 30-day case fatality rate was 16.9%. If one 
considers all 1,773 incident BSI cases in this study includ-
ing patients managed in the community and in hospital, the 
242 deaths identified in hospital represent a much smaller 
proportion (13.6%) overall. Notably, had we chosen a longer 
duration of follow-up these differences would have been more 
pronounced (Figure 2). Our results are not surprising as one 
may reasonably predict that if deaths following discharge are 
not measured the rate will be lower. However, this issue is 
rarely raised in literature critique. Our data provide empiric 
evidence to demonstrate that the use of hospital death alone 
will fail to ascertain the true mortality outcome. These data 
not only question mortality outcomes used in research studies 
but raise concern about benchmarking between institutions 
based on inhospital case fatality. Ideally, all-cause defined 
case fatality rates at a specified outcome period should be 
used and where reliable population-level vital statistics data 
is not available, at the very least, attempts should be made to 
include patients who are transferred to hospice or palliative 
care programs.
Not only does inhospital death underestimate the case 
fatality rate but also it biases the evaluation of the determinants 
of death. We hypothesized in advance that there may be dif-
ferences in the clinical characteristics of patients among those 
dying in hospital vs those dying as outpatients within 30 days 
of BSI. Our observation that patients who died post discharge 
were older and more likely to have dementia supports this 
(Table 1). It is further possible that other comorbidities were 
truly different but that our study was underpowered to detect 
these. In our health system, there are limited hospice beds and 
it is possible that some of the inhospital deaths would have 
been post discharge and had there been ready access to these 
beds. However, we did not have data on all of our patients 
regarding curative or palliative treatment intent to evaluate 
this further. The difference among inhospital and 30-day case 
fatality rates in other jurisdictions will likely be dependent on 
the disposition of patients receiving palliative care.
Death is a discrete binary variable that is free from 
observer ascertainment bias. However, it is subject to bias if 
follow-up is incomplete or censored. We contend that many 
investigators and users of medical literature do not scrutinize 
the potential limitations of inhospital death as a measure of 
true defined follow-up death outcome and tend to consider 
these terms synonymous. Anecdotally, we rarely observe this 
issue as a discussion or limitation point in published studies 
Figure 2 all-cause case fatality rates and hospital disposition at the time of death during varying periods of follow-up, western interior of British Columbia, 2010–2017.
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hospital mortality is a biased measure of case fatality
and this includes our own previous work.14,15 To derive an 
estimate of the use of death as outcome in contemporary 
studies, we searched PubMed on March 9, 2018, using 
terms “mortality” and “bloodstream infection” and sampled 
the first ten original studies that involved human subjects 
with a reported and evaluable death outcome. Among these, 
one-half only evaluated inhospital outcomes including two 
studies that restricted to intensive care unit (ICU) outcome 
alone16,17 with the other three limited to inhospital death.18–20 
The other one-half of studies evaluated 30-day,21,22 90-day,23,24 
and 6-month25 all-cause deaths. We chose BSI to study this 
issue as a matter of convenience as we had ready access to 
a detailed population-based database. However, we suspect 
that the inhospital bias we observed is generalizable to many 
other conditions and jurisdictions and merits investigation 
elsewhere.
There are some methodological aspects of our study that 
merit discussion. It is a strength that we utilized a population-
based design that included all cases of incident BSI occur-
ring among residents of a well-defined geographical area. 
As a result, sampling bias was minimized.26 By virtue of 
this design, we were able to evaluate not only the number 
of patients who died and who were never admitted but also 
those who died after hospital admission. It is a limitation 
of our study that the review of clinical aspects of patients 
was retrospective and therefore ascertainment of diagnosis, 
comorbidities, and treatment intent was dependent on the 
information existing in the medical charts. It is also an 
important consideration that we made no attempt to adju-
dicate whether the BSI was causative in a patient’s death or 
not. Although it is probable that deaths within a short period 
of time following a BSI diagnosis are largely attributable to 
the infection, other determinants including comorbidities or 
downstream complications of the acute illness were likely 
increasingly causative for death in later stages of follow-up. In 
any case, attribution of cause of death to a specific disease is 
fraught with difficulty and the case for using all-cause death 
as an outcome measure has been convincingly argued.13 It 
is also noteworthy that we a priori defined an admission as 
a continuous event including interhospital transfers as this 
is common between our regional hospitals. Had we only 
included the index hospital admission we suspect that more 
pronounced findings would have been observed. Finally, we 
relied on the information registered in the electronic database 
to establish vital status without further formalized verifica-
tion. However, based on the fact that these data are populated 
from provincial vital statistics it is likely highly accurate.
Conclusion
We observe that in our population-based cohort of patients 
with BSI, inhospital death is a biased measure of true all-
cause case fatality. Not only the use of inhospital death 
underestimates the true death burden and this increases with 
the duration of follow-up, but also it introduces a bias in the 
evaluation of the determinants of death among study subjects. 
Inhospital death is commonly used as an outcome measure in 
published studies. Although the use of defined-day all-cause 
case fatality is not feasible, the limitations associated with 
inhospital death need to be emphasized in the interpretation 
of studies investigating the outcome of infectious diseases and 
other conditions. It is likely that the degree of bias associated 
with the use of inhospital death will vary among different 
institutions and populations, and further investigation in other 
jurisdictions is warranted.
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